Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for HS sufferers: Long-Term drug trial shows promise

NCT ID NCT06241573

Terminated Disease control Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at the long-term safety and effectiveness of spesolimab for people with hidradenitis suppurativa (HS), a painful skin condition. Participants who completed a prior spesolimab study receive injections under the skin every 2 weeks for about 1.5 years. The goal is to see how well the drug is tolerated and if it helps control HS over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA (HS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hidradenitis suppurativa

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIDRADENITIS SUPPURATIVA (HS)

Contacts and locations

Locations

  • ASMC-IPSMC-skin and Veneral Diseases

    Sofia, 1407, Bulgaria

  • Alfred Hospital

    Melbourne, Victoria, 3004, Australia

  • Clinical Trials Research Institute

    Thousand Oaks, California, 91320, United States

  • Dermatology Research Associates

    Los Angeles, California, 90045, United States

  • Dr. S. K. Siddha Medicine Professional Corporation

    Newmarket, Ontario, L3Y 5G8, Canada

  • Fachklinik Bad Bentheim

    Bad Bentheim, 48455, Germany

  • First OC Dermatology

    Fountain Valley, California, 92708, United States

  • Guelph Dermatology Research

    Guelph, Ontario, N1L 0B7, Canada

  • HOP Privé Antony

    Antony, 92160, France

  • Hautmedizin Saar

    Merzig, 66663, Germany

  • Holdsworth House Medical Practice

    Sydney, New South Wales, 2010, Australia

  • Hospital Alemán

    Capital Federal, C1118AAT, Argentina

  • Hospital Italiano de Buenos Aires

    CABA, C1199ABB, Argentina

  • Hospital Kuala Lumpur

    Kuala Lumpur, 50586, Malaysia

  • Hospital Pulau Pinang-Pulau Pinang-21953

    Georgetown Pulau Pinang, 10990, Malaysia

  • Hospital Sultan Ismail

    Johor Bahru, 81100, Malaysia

  • Hospital Universitario Miguel Servet

    Zaragoza, 50009, Spain

  • Hospital of Lithuanian University of Health Sciences Kauno Klinikos

    Kaunas, 50161, Lithuania

  • Hôpital Edouard Herriot

    Lyon, 69437, France

  • Integrative Skin Science and Research-Sacramento-69402

    Sacramento, California, 95815, United States

  • Kurume University Hospital

    Fukuoka, Kurume, 830-0011, Japan

  • Medical Center "Kordis"

    Pleven, 5800, Bulgaria

  • National University Hospital-Singapore-42005

    Singapore, 119074, Singapore

  • Nihon University Itabashi Hospital

    Tokyo, Itabashi-ku, 173-8610, Japan

  • Non-Public Health Care Facility LABDERM

    Ossy, 42624, Poland

  • Ogaki Municipal Hospital

    Gifu, Ogaki, 503-8502, Japan

  • Provita Clinic

    Warsaw, 02-647, Poland

  • Royalderm

    Warsaw, 02-962, Poland

  • STAT Research

    CABA, C1023AAB, Argentina

  • Sarawak General Hospital

    Kuching, 93586, Malaysia

  • Seoul National University Hospital

    Seoul, 03080, South Korea

  • SimcoDerm Medical and Surgical Dermatology Centre

    Barrie, Ontario, L4M 7G1, Canada

  • Sunway Medical Centre

    Selangor Darul Ehsan, 47500, Malaysia

  • The University of Tokyo Hospital

    Tokyo, Bunkyo-ku, 113-8655, Japan

  • Tokyo Medical University Hospital

    Tokyo, Shinjuku-ku, 160-0023, Japan

  • Vilnius University Hospital, Santariskiu

    Vilnius, 08411, Lithuania

More trials for these conditions

Other studies related to the condition(s) this trial covers.